FOXO Technologies Inc. (FOXO) presents a deeply negative liquidation posture as of March 31, 2026. MFFAIS data places cash liquidation value at approximately negative $35.6 million, liquid liquidation value at negative $33.1 million, and operating liquidation value at negative $32.9 million. These figures are consistent with the balance sheet structure disclosed in the filing: cash of $66K, working capital deficit of $27.1 million, and total debt (net of discounts) of $8.6 million as of period end. Under a liquidation lens, the gap between recoverable asset value and face-value liabilities is structurally large and widening. Cash is the only hard-recovery asset disclosed at any meaningful level, and at $66K it is effectively immaterial. The filing does not separately tag any balance sheet line items in XBRL for this quarter, preventing line-by-line tag analysis. All material balance sheet disclosures are therefore addressed here in the narrative. The working capital deficit deteriorated from $25.5 million at December 31, 2025 to $27.1 million at March 31, 2026, driven by $1.3 million of net debt increase and continued operating losses. Total debt (gross face value approximately $8.7 million before discounts) is composed of: third-party promissory notes of $3.2 million principal (net of $0.1 million discounts); related-party notes and loans payable to RHI and affiliates totaling $4.5 million; and other loans of $82K. Multiple notes across both categories are in default. The Western Note is in default with no probable further conversion. The $1.0 million RHI note is in default and extension discussions are ongoing. Illumina settlement payments are in default ($723K remaining). Func.media settlement is in default. These defaults do not appear to have triggered acceleration or cross-default cascade disclosures in the filing, but each represents a face-value liability not subject to haircut in a liquidation scenario. A critical post-period development: on May 12, 2026 (subsequent event), institutional investors exchanged their Series A Preferred Stock for senior unsecured non-convertible promissory notes totaling $7.8 million aggregate principal ($5.3 million to one holder, $2.5 million to another), due May 12, 2027 or upon a liquidity event, with 18% default interest. This exchange removes the Series A overhang that blocked the FINRA reverse split approval but adds $7.8 million of hard-dollar senior debt to the liability stack post-period — a material deterioration in recovery posture not reflected in the March 31 balance sheet. The filing discusses this in MD&A and Note 16 but, consistent with the empty TAG_CONTEXT, no XBRL tags are reported for this filing period. The total goodwill and intangible asset base embedded in the $40.9 million Healthcare segment (per the prior 10-K segment asset table) is assigned zero recovery under the liquidation lens. FOXO Labs intangibles have been impaired to zero per management's own disclosure. PP&E at the hospital campus and behavioral health facility may carry some 50-70% recovery value, but the filing does not separately quantify PP&E, and most of the stated asset base in Healthcare is goodwill from related-party acquisitions structured as stock-for-stock exchanges — all zero-recovery items. The healthcare segment generated positive segment income of $297K in Q1 2026 (vs. loss of $845K in Q1 2025), a meaningful operational improvement driven by swing-bed revenue growth at BSF, but this income generation does not alter the liquidation posture given the liability stack. Multiple unresolved legal contingencies (former CEO severance claim, Gateway Group $120K, Data Shepherd $58K judgment, Illumina default) represent additional unlisted face-value liabilities in a wind-down. Material weaknesses in internal controls continue, and the CFO resigned in March 2026 citing control environment concerns — heightening uncertainty around the accuracy of the reported figures. Going concern doubt is explicitly disclosed.
▼ Community Notes